Stoke Therapeutics (STOK) Operating Expenses (2018 - 2026)

Stoke Therapeutics' Operating Expenses history runs 9 years deep, the most recent figure standing at $59.6 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 26.03% year-over-year to $59.6 million in Q1 2026; TTM through Mar 2026 was $324.8 million, a 184.39% increase from a year earlier, with the FY2025 full-year figure at $205.0 million, up 48.64% from the prior year.
• Operating Expenses declined to $59.6 million in Q1 2026 per STOK's latest filing, from $215.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $215.2 million in Q4 2025 and bottomed at -$101.2 million in Q4 2023.
• The 5-year median for Operating Expenses is $30.5 million (2023), against an average of $34.0 million.
• Across the five-year window, Operating Expenses plunged 432.54% in 2023 and soared 1603.58% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $30.4 million in 2022, then plunged by 432.54% to -$101.2 million in 2023, then surged by 135.82% to $36.3 million in 2024, then jumped by 493.4% to $215.2 million in 2025, then tumbled by 72.28% to $59.6 million in 2026.
• Per Business Quant, the three latest STOK Operating Expenses figures stand at $59.6 million (Q1 2026), $215.2 million (Q4 2025), and $53.7 million (Q3 2025).